It is possible that BM-PCa tumors in bone display heterogeneous STAT5 expression, as previously identified in primary PCa tumors with intratumor variability in STAT5 protein levels [33], such that neutrophil targeting would inevitably result in the emergence of a neutrophil-resistant population, similar to acquired drug resistance. The gene discussed is STAT5A; the disease is posterior cortical atrophy.